在TD Cowen会议上，吉利德科学的高管透露，若将Anito-Cel应用于一线治疗，该疗法有望覆盖多发性骨髓瘤领域“高达200亿美元”的市场机遇。
这一表态凸显了Anito-Cel在拓展治疗窗口方面的巨大潜力，特别是其在早期治疗阶段可能带来的商业价值。多发性骨髓瘤作为一种恶性血液肿瘤，一线治疗市场的规模庞大，Anito-Cel若能成功切入，将显著提升吉利德在肿瘤治疗领域的竞争力。
值得注意的是，这一评估基于对现有市场格局和未满足临床需求的深入分析。随着细胞疗法在血液肿瘤领域的不断突破，Anito-Cel的商业前景备受关注。吉利德的战略布局也反映出其对创新疗法长期价值的坚定信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.